Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Bradford Crutchfield. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Bradford Crutchfield har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:TXG / 10x Genomics, Inc. | Chief Commercial Officer | 97 237 |
US:BIO / Bio-Rad Laboratories, Inc. | Executive Vice President | 0 |
US:NSTG / NanoString Technologies, Inc. | Director | 5 847 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Bradford Crutchfield. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp BIO / Bio-Rad Laboratories, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i BIO / Bio-Rad Laboratories, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i BIO / Bio-Rad Laboratories, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp TXG / 10x Genomics, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i BIO / Bio-Rad Laboratories, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-13 | TXG | CRUTCHFIELD BRADFORD | 158 | 40,4855 | 158 | 40,4855 | 6 397 | 322 | 55.7900 | 2 419 | 37,82 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i BIO / Bio-Rad Laboratories, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Bradford Crutchfield som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −286 | 97 237 | −0,29 | 48,76 | −13 947 | 4 741 685 | |
2022-05-17 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
P - Purchase | 158 | 97 523 | 0,16 | 40,49 | 6 397 | 3 948 267 | |
2022-02-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −288 | 97 365 | −0,29 | 78,60 | −22 637 | 7 652 821 | |
2022-02-17 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 392 000 | −4,16 | |||
2022-02-17 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −17 000 | 97 653 | −14,83 | 95,13 | −1 617 261 | 9 290 023 |
2022-02-17 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 114 653 | 17,41 | 1,16 | 19 720 | 132 997 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 409 000 | −3,99 | |||
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 | 97 653 | 0,00 | 125,00 | −375 | 12 206 625 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 97 656 | −0,10 | 124,44 | −12 444 | 12 152 313 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 97 756 | −0,10 | 123,53 | −12 353 | 12 075 799 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 97 856 | −0,10 | 122,94 | −12 294 | 12 030 417 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 200 | 97 956 | −3,16 | 121,76 | −389 648 | 11 927 612 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 100 | 101 156 | −1,08 | 120,93 | −133 025 | 12 232 937 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 017 | 102 256 | −0,98 | 119,28 | −121 311 | 12 197 443 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 185 | 103 273 | −4,78 | 118,32 | −613 499 | 12 219 447 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 195 | 108 458 | −5,40 | 117,53 | −728 071 | 12 746 592 |
2022-01-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 114 653 | 17,41 | 1,16 | 19 720 | 132 997 |
2021-12-23 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −49 910 | 61 757 | −44,70 | ||||
2021-12-23 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −4 688 | 0 | −100,00 | ||||
2021-12-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 49 910 | 97 653 | 104,54 | 5,04 | 251 546 | 492 171 | |
2021-12-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 4 688 | 47 743 | 10,89 | 1,20 | 5 626 | 57 292 | |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 426 000 | −3,84 | |||
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 43 055 | −0,23 | 142,47 | −14 247 | 6 134 046 |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 43 155 | −1,82 | 141,31 | −113 049 | 6 098 276 |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 701 | 43 955 | −3,73 | 140,38 | −238 792 | 6 170 544 |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −9 599 | 45 656 | −17,37 | 139,52 | −1 339 239 | 6 369 861 |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 235 | 55 255 | −5,53 | 138,60 | −448 374 | 7 658 393 |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 565 | 58 490 | −2,61 | 137,63 | −215 396 | 8 050 160 |
2021-12-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 055 | 39,48 | 1,16 | 19 720 | 69 664 |
2021-11-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −281 | 43 055 | −0,65 | 148,38 | −41 695 | 6 388 548 | |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 443 000 | −3,70 | |||
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 43 336 | −0,23 | 168,34 | −16 834 | 7 295 182 |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 43 436 | −0,23 | 167,27 | −16 727 | 7 265 540 |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 776 | 43 536 | −9,89 | 165,89 | −792 306 | 7 222 326 |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 872 | 48 312 | −12,45 | 164,87 | −1 132 963 | 7 965 030 |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 122 | 55 184 | −6,95 | 164,18 | −676 733 | 9 059 888 |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 030 | 59 306 | −1,71 | 163,10 | −167 994 | 9 672 886 |
2021-11-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 336 | 39,23 | 1,16 | 19 720 | 69 990 |
2021-10-14 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 460 000 | −3,56 | |||
2021-10-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 043 | 43 336 | −6,56 | 158,63 | −482 716 | 6 874 455 |
2021-10-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −7 997 | 46 379 | −14,71 | 157,40 | −1 258 760 | 7 300 240 |
2021-10-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 960 | 54 376 | −9,88 | 156,49 | −932 678 | 8 509 278 |
2021-10-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 336 | 39,23 | 1,16 | 19 720 | 69 990 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 477 000 | −3,44 | |||
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 43 336 | −0,23 | 184,32 | −18 432 | 7 987 692 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 43 436 | −0,23 | 181,24 | −18 124 | 7 872 123 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 43 536 | −1,14 | 178,90 | −89 451 | 7 788 677 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 000 | 44 036 | −2,22 | 178,24 | −178 237 | 7 848 845 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 700 | 45 036 | −3,64 | 177,21 | −301 259 | 7 980 870 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 906 | 46 736 | −7,71 | 176,19 | −688 198 | 8 234 411 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 694 | 50 642 | −5,05 | 175,17 | −471 900 | 8 870 802 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 53 336 | −4,82 | 174,14 | −470 166 | 9 287 686 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 56 036 | −0,71 | 172,40 | −68 958 | 9 660 326 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 56 436 | −0,53 | 171,20 | −51 361 | 9 662 029 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 300 | 56 736 | −2,24 | 170,30 | −221 394 | 9 662 334 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 300 | 58 036 | −3,81 | 169,06 | −388 834 | 9 811 462 |
2021-09-15 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 336 | 39,23 | 1,16 | 19 720 | 69 990 |
2021-08-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −270 | 43 336 | −0,62 | 161,85 | −43 699 | 7 013 823 | |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 494 000 | −3,33 | |||
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 43 606 | −1,80 | 161,84 | −129 472 | 7 057 195 |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 087 | 44 406 | −10,28 | 161,28 | −820 436 | 7 161 840 |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 400 | 49 493 | −6,43 | 160,00 | −544 011 | 7 919 038 |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 213 | 52 893 | −5,73 | 159,13 | −511 290 | 8 416 942 |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 400 | 56 106 | −4,10 | 158,07 | −379 374 | 8 868 804 |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 100 | 58 506 | −3,47 | 157,19 | −330 100 | 9 196 576 |
2021-08-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 606 | 38,99 | 1,16 | 19 720 | 70 303 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 511 000 | −3,22 | |||
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 43 606 | −0,68 | 191,60 | −57 481 | 8 354 984 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 43 906 | −1,35 | 190,86 | −114 518 | 8 380 022 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 44 506 | −1,11 | 189,36 | −94 682 | 8 427 834 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 512 | 45 006 | −3,25 | 188,32 | −284 733 | 8 475 318 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 933 | 46 518 | −7,80 | 187,31 | −736 674 | 8 713 101 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 400 | 50 451 | −8,02 | 185,87 | −817 811 | 9 377 136 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 755 | 54 851 | −9,50 | 185,07 | −1 065 097 | 10 151 461 |
2021-07-14 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 606 | 38,99 | 1,16 | 19 720 | 70 303 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 528 000 | −3,12 | |||
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 43 262 | −0,92 | 193,64 | −77 456 | 8 377 254 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 100 | 43 662 | −10,46 | 192,97 | −984 128 | 8 425 290 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 500 | 48 762 | −8,45 | 192,12 | −864 535 | 9 368 102 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 000 | 53 262 | −5,33 | 191,16 | −573 476 | 10 181 484 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 084 | 56 262 | −5,20 | 190,01 | −585 995 | 10 690 416 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −916 | 59 346 | −1,52 | 189,03 | −173 147 | 11 217 907 |
2021-06-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 60 262 | 39,30 | 1,16 | 19 720 | 69 904 |
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −281 | 43 262 | −0,65 | 162,66 | −45 707 | 7 036 980 | |
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
A - Award | 22 338 | 22 338 | |||||
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 8 935 | 43 543 | 25,82 | ||||
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 545 000 | −3,02 | |||
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 34 608 | −0,29 | 137,57 | −13 757 | 4 761 023 |
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 34 708 | −3,34 | 136,80 | −164 164 | 4 748 169 |
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 702 | 35 908 | −7,00 | 135,74 | −366 781 | 4 874 310 |
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −7 875 | 38 610 | −16,94 | 134,70 | −1 060 759 | 5 200 752 |
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 123 | 46 485 | −9,93 | 133,86 | −685 759 | 6 222 431 |
2021-05-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 51 608 | 49,12 | 1,16 | 19 720 | 59 865 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 562 000 | −2,94 | |||
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 34 608 | −0,86 | 192,17 | −57 652 | 6 650 734 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 100 | 34 908 | −3,05 | 190,31 | −209 340 | 6 643 324 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 400 | 36 008 | −3,74 | 189,34 | −265 075 | 6 817 737 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 398 | 37 408 | −6,02 | 188,36 | −451 695 | 7 046 287 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 996 | 39 806 | −4,77 | 187,10 | −373 450 | 7 447 667 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 855 | 41 802 | −6,39 | 186,31 | −531 911 | 7 788 068 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 500 | 44 657 | −3,25 | 185,14 | −277 714 | 8 267 918 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 46 157 | −1,28 | 184,32 | −110 591 | 8 507 594 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 302 | 46 757 | −2,71 | 182,75 | −237 938 | 8 544 744 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 642 | 48 059 | −5,21 | 181,84 | −480 426 | 8 739 140 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −907 | 50 701 | −1,76 | 181,10 | −164 260 | 9 182 098 |
2021-04-13 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 51 608 | 49,12 | 1,16 | 19 720 | 59 865 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 579 000 | −2,85 | |||
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 100 | 34 608 | −5,72 | 159,51 | −334 977 | 5 520 419 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 176 | 36 708 | −7,96 | 158,85 | −504 513 | 5 831 128 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 211 | 39 884 | −5,25 | 157,70 | −348 684 | 6 289 866 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 606 | 42 095 | −7,89 | 156,52 | −564 404 | 6 588 629 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 807 | 45 701 | −7,69 | 155,54 | −592 148 | 7 108 425 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 100 | 49 508 | −4,07 | 154,52 | −324 492 | 7 649 966 |
2021-03-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 51 608 | 49,12 | 1,16 | 19 720 | 59 865 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 596 000 | −2,77 | |||
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 34 608 | −0,57 | 178,92 | −35 783 | 6 191 890 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −900 | 34 808 | −2,52 | 177,86 | −160 073 | 6 190 930 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 35 708 | −7,03 | 176,94 | −477 751 | 6 318 348 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −8 451 | 38 408 | −18,03 | 175,94 | −1 486 839 | 6 757 369 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 003 | 46 859 | −7,87 | 175,25 | −701 522 | 8 211 998 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −746 | 50 862 | −1,45 | 173,99 | −129 796 | 8 849 459 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 51 608 | 49,12 | 1,16 | 19 720 | 59 865 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 613 000 | −2,70 | |||
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 34 608 | −1,14 | 141,77 | −56 708 | 4 906 376 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 135 | 35 008 | −8,22 | 140,74 | −441 211 | 4 926 928 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −10 465 | 38 143 | −21,53 | 139,89 | −1 463 947 | 5 335 817 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 000 | 48 608 | −5,81 | 138,97 | −416 908 | 6 755 015 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 51 608 | 49,12 | 1,16 | 19 720 | 59 865 |
2020-12-30 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −13 333 | 111 667 | −10,67 | ||||
2020-12-30 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −20 312 | 4 688 | −81,25 | ||||
2020-12-30 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 13 333 | 34 608 | 62,67 | 5,04 | 67 198 | 174 424 | |
2020-12-30 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 20 312 | 21 275 | 2 109,24 | 1,20 | 24 374 | 25 530 | |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 630 000 | −2,63 | |||
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 718 | 963 | −64,08 | 153,58 | −263 852 | 147 899 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 410 | 2 681 | −47,34 | 152,96 | −368 628 | 410 080 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 295 | 5 091 | −31,07 | 151,68 | −348 096 | 772 183 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 496 | 7 386 | −42,66 | 150,87 | −829 161 | 1 114 298 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 081 | 12 882 | −28,29 | 150,02 | −762 245 | 1 932 540 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 963 | 1 765,32 | 1,16 | 19 720 | 20 837 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −6 496 | 647 000 | −0,99 | |||
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 963 | −17,20 | 138,43 | −27 686 | 133 308 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 898 | 1 163 | −77,02 | 137,56 | −536 203 | 159 980 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 198 | 5 061 | −30,28 | 136,60 | −300 255 | 691 351 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 7 259 | −2,68 | 135,42 | −27 084 | 983 014 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 6 496 | 7 459 | 674,56 | 1,16 | 7 535 | 8 652 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 504 | 653 496 | −1,58 | |||
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 963 | −29,35 | 139,24 | −55 698 | 134 093 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 1 363 | −36,99 | 138,40 | −110 719 | 188 638 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 2 163 | −35,68 | 136,97 | −164 361 | 296 260 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 604 | 3 363 | −66,26 | 136,06 | −898 572 | 457 586 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 500 | 9 967 | −13,08 | 135,29 | −202 938 | 1 348 455 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 504 | 11 467 | 1 090,76 | 1,16 | 12 185 | 13 302 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 664 000 | −2,50 | |||
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 963 | −23,75 | 126,88 | −38 064 | 122 185 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 475 | 1 263 | −73,34 | 125,99 | −437 822 | 159 128 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −10 725 | 4 738 | −69,36 | 125,48 | −1 345 731 | 594 506 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 15 463 | −13,92 | 124,26 | −310 643 | 1 921 389 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 963 | 1 765,32 | 1,16 | 19 720 | 20 837 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −3 224 | 681 000 | −0,47 | |||
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −50 | 963 | −4,94 | 114,89 | −5 744 | 110 639 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −150 | 1 013 | −12,90 | 114,10 | −17 115 | 115 583 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −528 | 1 163 | −31,22 | 113,18 | −59 759 | 131 628 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 496 | 1 691 | −46,94 | 112,32 | −168 035 | 189 938 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 000 | 3 187 | −23,88 | 111,33 | −111 327 | 354 800 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 3 224 | 4 187 | 334,79 | 1,16 | 3 740 | 4 857 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −13 776 | 684 224 | −1,97 | |||
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 963 | −34,18 | 115,41 | −57 704 | 111 139 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 789 | 1 463 | −76,60 | 114,65 | −549 039 | 167 727 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 887 | 6 252 | −48,50 | 113,82 | −670 067 | 711 611 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 600 | 12 139 | −17,64 | 112,92 | −293 593 | 1 370 741 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 13 776 | 14 739 | 1 430,53 | 1,16 | 15 980 | 17 097 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 698 000 | −2,38 | |||
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 963 | −55,48 | 100,72 | −120 859 | 96 989 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −8 342 | 2 163 | −79,41 | 99,47 | −829 818 | 215 164 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −7 458 | 10 505 | −41,52 | 98,94 | −737 930 | 1 039 414 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 963 | 1 765,32 | 1,16 | 19 720 | 20 837 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 715 000 | −2,32 | |||
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 0 | −100,00 | 88,73 | −44 366 | |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −8 900 | 500 | −94,68 | 87,94 | −782 708 | 43 972 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −7 600 | 9 400 | −44,71 | 87,11 | −662 062 | 818 866 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 000 | 1,16 | 19 720 | 19 720 | |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 732 000 | −2,27 | |||
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 000 | 0 | −100,00 | 81,92 | −163 844 | |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 900 | 2 000 | −71,01 | 81,39 | −398 801 | 162 776 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 6 900 | −26,60 | 80,05 | −200 132 | 552 364 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 9 400 | −21,01 | 79,14 | −197 845 | 743 897 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 400 | 11 900 | −22,22 | 78,06 | −265 420 | 928 969 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 700 | 15 300 | −10,00 | 77,17 | −131 182 | 1 180 638 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 000 | 1,16 | 19 720 | 19 720 | |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 749 000 | −2,22 | |||
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 0 | −100,00 | 79,23 | −23 769 | |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 200 | 300 | −93,33 | 78,66 | −330 370 | 23 598 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 695 | 4 500 | −45,09 | 77,57 | −286 634 | 349 080 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −8 805 | 8 195 | −51,79 | 76,63 | −674 696 | 627 954 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 000 | 1,16 | 19 720 | 19 720 | |
2020-04-23 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
A - Award | 90 667 | 90 667 | |||||
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 766 000 | −2,17 | |||
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 0 | −100,00 | 59,62 | −23 848 | |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −7 789 | 400 | −95,12 | 58,33 | −454 318 | 23 331 |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −8 811 | 8 189 | −51,83 | 57,75 | −508 840 | 472 919 |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 000 | 1,16 | 19 720 | 19 720 | |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −17 000 | 783 000 | −2,12 | |||
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −41 | 0 | −100,00 | 70,35 | −2 884 | |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 800 | 41 | −99,30 | 69,10 | −400 777 | 2 833 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −546 | 5 841 | −8,55 | 68,19 | −37 230 | 398 277 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 6 387 | −8,59 | 66,85 | −40 112 | 426 992 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 6 987 | −14,66 | 65,71 | −78 855 | 459 133 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 513 | 8 187 | −15,60 | 64,78 | −98 009 | 530 336 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 110 | 9 700 | −34,50 | 63,69 | −325 477 | 617 833 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 190 | 14 810 | −12,88 | 62,62 | −137 133 | 927 368 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 17 000 | 17 000 | 1,16 | 19 720 | 19 720 | |
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 70 000 | 70 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −70 000 | 0 | −100,00 | ||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 125 000 | 125 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −125 000 | 0 | −100,00 | ||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 25 000 | 25 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −25 000 | 0 | −100,00 | ||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 800 000 | 800 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −800 000 | 0 | −100,00 | ||||
2014-06-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 0 | −100,00 | ||||
2014-06-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
F - Taxes | −90 | 5 332 | −1,66 | 121,96 | −10 976 | 650 291 | |
2014-06-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 5 422 | 4,63 | ||||
2014-01-03 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 5 847 | 5 847 | |||||
2013-11-19 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 000 | 0 | −100,00 | ||||
2013-11-19 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
F - Taxes | −2 592 | 7 146 | −26,61 | 123,24 | −319 376 | 880 735 | |
2013-11-19 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 4 000 | 9 738 | 69,71 | 53,75 | 215 000 | 523 418 | |
2013-11-05 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 720 | −25,00 | ||||
2013-11-05 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 7 223 | 3,44 | ||||
2013-09-13 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 960 | −20,00 | ||||
2013-09-13 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 6 983 | 3,56 | ||||
2013-09-13 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Non-Qualified Stock Option (right to buy) |
A - Award | 3 200 | 3 200 | |||||
2013-09-13 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
A - Award | 1 200 | 1 200 | |||||
2013-09-10 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 480 | −33,33 | ||||
2013-09-10 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 6 743 | 3,69 | ||||
2013-06-27 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 11 686 | 11 686 | |||||
2013-06-25 | 3 | NSTG |
NanoString Technologies Inc
No securities are beneficially owned |
0 | ||||||||
2013-06-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 240 | −50,00 | ||||
2013-06-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 6 503 | 3,83 | ||||
2012-11-06 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 960 | −20,00 | ||||
2012-11-06 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 6 263 | 3,98 | ||||
2012-09-14 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Non-Qualified Stock Option (right to buy) |
A - Award | 3 250 | 3 250 | |||||
2012-09-14 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
A - Award | 1 200 | 1 200 | |||||
2012-09-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
S - Sale | −92 | 6 023 | −1,50 | 103,49 | −9 521 | 623 323 | |
2012-09-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 720 | −25,00 | ||||
2012-09-11 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 6 115 | 4,09 | ||||
2012-08-21 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 130 | 0 | −100,00 | ||||
2012-08-21 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Incentive Stock Option (right to buy) |
M - Exercise | −2 870 | 0 | −100,00 | ||||
2012-08-21 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
S - Sale | −4 000 | 5 875 | −40,51 | 103,11 | −412 438 | 605 769 | |
2012-08-21 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 4 000 | 9 875 | 68,09 | 35,50 | 142 000 | 350 562 | |
2012-06-13 |
|
4 | BIO, BIO.B |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
S - Sale | −87 | 5 875 | −1,46 | 96,51 | −8 396 | 566 996 | |
2012-06-12 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
S - Sale | −89 | 5 962 | −1,47 | 96,49 | −8 588 | 575 273 | |
2012-06-12 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Restricted Stock Units |
M - Exercise | −240 | 480 | −33,33 | ||||
2012-06-12 |
|
4 | BIO, BIOB |
BIO RAD LABORATORIES INC
Bio-Rad A Common Stock |
M - Exercise | 240 | 6 051 | 4,13 |